The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) is a network of nine leading liver transplantation centers in the United States and Canada, assembled by the National Institutes of Health in 2002, and works under a cooperative agreement with the University of Michigan and Arbor Research. The A2ALL study is designed to answer questions about safety and outcomes for donors and recipients of living liver donation.
Living donor liver transplantation has the potential to streamline the future of liver transplantation by avoiding lengthy waiting periods for a deceased donor transplant, reducing ischemic time with scheduled procedures, and allowing for longer evaluation of the donor and recipient, possibly leading to decreased mortality and better long-term outcomes. However, prior to the A2ALL project, there were few answers for living liver donors about their future medical outcomes and quality of life. The A2ALL study represents the largest and longest study of living liver donors in the United States. Comprehensive reports from the A2ALL help inform the transplant community, and serve as a benchmark for future interventions and strategies that measure and reduce risks to donors and recipients alike.
In this talk presented at the UCSF Liver Transplant Conference, Chris Freise, MD discusses the overview and results of the A2ALL Adult to Adult Living Donor Liver Transplantation Cohort Study. He compares which pathway to transplant lead to the best survival, and looks at the differences in living or deceased donor transplant survival rates. Recorded on 11/14/2014.